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Background & aims: Non-alcoholic fatty liver disease (NAFLD) is a liver condition characterised by liver
fat accumulation and often considered to be the liver manifestation of metabolic syndrome. The aim
of this study was to examine in patients with NAFLD the system-wide effects of treatment with doco-
sahexaenoic acid þ eicosapentaenoic acid (DHA þ EPA) versus placebo on the plasma proteome.
Methods: Plasma from patients that participated in a 15e18 months randomised, double-blind placebo-
controlled trial testing the effects of 4 g DHA þ EPA daily was analysed using depletion-free quantitative
proteomics.
Results: Bioinformatics interpretation of the proteomic analysis showed that DHAþ EPA treatment affected
pathways involving blood coagulation, immune/inﬂammatory response and cholesterol metabolism
(p < 0.05). Two key proteins of cardiovascular risk, prothrombin and apolipoprotein B-100, were shown to
decrease as a result of DHAþ EPA supplementation [Prothrombin: Males DHAþ EPAMean iTRAQ log2ratio
(SD) ¼ 0.13 (0.20) p ¼ 0.05, Females DHA þ EPA Mean iTRAQ log2ratio (SD) ¼ 0.48 (0.35) p ¼ 0.03; Apo
B-100: Males DHA þ EPA Mean iTRAQ log2ratio (SD) ¼ 0.24 (0.16) p ¼ 0.01, Females DHA þ EPA Mean
iTRAQ log2ratio (SD) ¼ 0.15 (0.05) p ¼ 0.02].
Conclusions: Plasma proteomics applied in a randomised, placebo-controlled trial showed that high dose
DHA þ EPA treatment in patients with NAFLD affects multiple pathways involved in chronic non-
communicable diseases.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Non-alcoholic fatty liver disease (NAFLD), a liver condition
characterised by liver fat accumulation 5%, is often considered todisease; CVD, cardiovascular
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co-senior authors.
r Ltd. This is an open access articlebe the liver manifestation of metabolic syndrome and is strongly
associated with obesity, type 2 diabetes mellitus and cardiovascular
disease (CVD) [1]. We have recently shown that after treatment
with high dose (3.36 g/day) marine omega-3 fatty acids [eicosa-
pentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA,
22:6n-3)] for 15e18 months in patients with NAFLD, serum fasting
triglyceride levels decreased, and that increased tissue enrichment
with DHA was associated with decreased liver fat, suggesting that
high-dose DHA þ EPA treatment may have a favourable effect on
cardiovascular risk in patients with NAFLD [2].
Global plasma proteomic analysis can provide unbiased insight
into the systemic effects of an intervention. The plasma proteomicunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fatty acids within the context of a randomised placebo-controlled
trial (RCT) has not been studied to date.
Therefore, the aim of the present study was to use a non-
targeted quantitative plasma proteomics approach to determine
the system-wide effects of high-dose DHA þ EPA supplementation
in patients with NAFLD who participated in a 15e18 month
randomized control trial.
Materials and methods
Recruitment of participants and intervention
The WELCOME study intervention protocol and inclusion/exclu-
sion criteria have been described in detail previously [3]. This clinical
trial was registered at ClinicalTrials.gov (www.clinicalTrials.gov
registration number NCT00760513). The study received ethical
approval from the Southampton and South West Hampshire local
research ethics committee (08/H0502/165). All participants signed
informed consent forms and underwent an assessment of liver fat
percentage by magnetic resonance spectroscopy (MRS) at recruit-
ment, to establish the baseline liver fat percentage at entry into the
trial, and at follow-up. Brieﬂy, three 20 20 20mm3 spectroscopic
volumes of interest (VOI) were positioned within segments 3 (infe-
rior sub-segment of the lateral segment), 5 (inferior sub-segment of
the anterior segment) and 8 (superior sub-segment of the anterior
segment) of the liver, avoidingmajor blood vessels, intra-hepatic bile
ducts, and the lateral margin of the liver. For the second visit scan,
these VOI positions were copied from the ﬁrst scan, to ensure con-
sistency [2,3]. Brieﬂy, the inclusion criteria for participation in the
study were age >18 years and: 1) a recent (<3 years) histological
diagnosis of non-alcoholic steatosis or steatohepatitis in keepingwith
NAFLD; or 2) steatosis diagnosed by ultrasound, CT or magnetic
resonance imaging in a patient who also had either diabetes and/or
features of the metabolic syndrome. All participants underwent an
assessment of liver fat percentage by MRS examination at recruit-
ment, to establish the baseline liver fat percentage at entry into the
trial. Exclusion criteria included known other causes of liver disease
(e.g. hepatitis A, B or C, primary biliary cirrhosis, Wilson's disease,
autoimmune hepatitis and haemochromatosis). These conditions
were excluded with blood tests. Subjects were also excluded if
alcohol consumption was >35 units per week for women and >50
units perweek formen. At recruitment, only onemanwas consuming
>21 units of alcohol per week and one woman was consuming >14
units per week. Additional exclusion criteria were: decompensated
acute or chronic liver disease; cirrhosis; pregnancy or breast feeding;
and hypersensitivity to Omacor, soya or any of the excipients. One-
hundred and three participants with NAFLD (sex M/F: 60/43) were
randomised to Omacor (DHA þ EPA) or placebo (olive oil). Fifty-one
(sex M/F: 25/26) participants received 3.36 g daily of DHA þ EPA
(1 g of Omacor contains 460 mg of EPA and 380 mg of DHA as ethyl
esters) and 52participants (sexM/F: 35/17) received 4 g of olive oil. At
the end of the study, 95 participants completed the intervention
period (DHA þ EPA group n ¼ 47, sex M/F: 24/23; Placebo group
n ¼ 48, sex M/F: 32/16). Fasting blood samples at baseline and after
the end of the intervention (15e18 months duration) were collected.
Plasma procurement and proteomic analysis
Two multiplex experiments were performed for men and
women participants respectively, to correct for potential baseline
sex-speciﬁc plasma proteome differences and sex-dependent
effects of the omega-3 intervention. Only plasma from patients
who completed the intervention was used for the proteomic
analysis (n ¼ 95; DHA þ EPA group n ¼ 47; Placebo group n ¼ 48).Individual 50 mL aliquots from male participants in the DHA þ EPA
and placebo groups were randomly pooled using the randomiza-
tion function in Microsoft Excel (version 15.11.1) at baseline and
after the end of the intervention to form two biological replicates
per time-point and treatment group [Males Baseline DHA þ EPA 1
(n ¼ 12), Males Baseline DHA þ EPA 2 (n ¼ 12), Males Baseline
Placebo 1 (n¼ 16), Males Baseline Placebo 2 (n¼ 16), Males End-of-
Study DHA þ EPA 1 (n ¼ 12), Males End-of-Study DHA þ EPA 2
(n ¼ 12), Males End-of-Study Placebo 1 (n ¼ 16), Males End-of-
Study Placebo 2 (n ¼ 16)]. The same pooling scheme was applied
for female participants [Females Baseline DHA þ EPA 1 (n ¼ 11),
Females Baseline DHAþ EPA 2 (n¼ 12), Females Baseline Placebo 1
(n ¼ 8), Females Baseline Placebo 2 (n ¼ 8), Females End-of-Study
DHAþ EPA 1 (n¼ 12), Females End-of-Study DHAþ EPA 2 (n¼ 11),
Females End-of-Study Placebo 1 (n ¼ 8), Females End-of-Study
Placebo 2 (n ¼ 8)]. Unprocessed plasma was subjected to
depletion-free proteomic analysis as reported elsewhere [4].
Database searching and statistics
Unprocessed raw ﬁles were submitted to Proteome Discoverer
1.4 for target decoy searching against the SwissProt homo sapiens
database (v2015-11-11) as reported previously4. Proteins reported
were analysed with a peptide level FDR p < 0.05. All mass
spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE partner repository with the
dataset identiﬁer PXD003760.
A two-tailed unpaired T-Test was used to identify proteins
that changed (end-of-study vs. baseline) differentially between the
DHA þ EPA and placebo groups of each sex. A value for p  0.05 was
considered signiﬁcant. According to the Paris Publication Guidelines
(http://www.mcponline.org/site/misc/ParisReport_Final.xhtml), only
proteins identiﬁedwith at least two unique peptideswere considered.
Bioinformatics analysis
Principal component analysis using the log2ratios of the fully
quantiﬁed proteins in each experiment (males and females
respectively) was performed using the online tool ClustVis (http://
biit.cs.ut.ee/clustvis/). MetaCore (GeneGo, St. Joseph, MI, USA) and
Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Germany) were
applied to identify biological processes and protein networks
signiﬁcantly enriched in the plasma proteins altered as a result of
the omega-3 fatty acid intervention. In all analyses, a false discov-
ery rate (FDR) corrected p-value < 0.05 was considered signiﬁcant.
Results
The participants’ baseline characteristics have been reported
previously [3] and are also presented in Supplementary Table 1.
A total of 1699 and 2084 proteins were fully quantiﬁed in the
multiplex experiment of the male and female cohorts respectively.
Principal component analysis using the reporter ion log2ratios of all
proﬁled proteins showed that the DHA þ EPA group clustered
separately from the placebo group for both male and female co-
horts, indicating that change (end-of-study vs. baseline) in plasma
proteins was different between DHA þ EPA and placebo groups
(Fig. 1A). In the male and female DHA þ EPA group compared to
placebo, 221 and 213 proteins respectively were signiﬁcantly
altered at the end-of-study vs. baseline (Supplementary Tables 2
and 3 respectively for male and female cohorts).
Process Network Analysis using MetaCore showed that blood
coagulation, immune response and inﬂammatory response were
signiﬁcantly enriched networks in the plasma proteins of both sexes
that were altered as a result of the omega-3 intervention (Fig. 1B).
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expression following DHA þ EPA supplementation in the male and
female cohorts (Fig.1C). Of the eleven proteins that were found to be
affected by DHA þ EPA supplementation in a sex-independent
manner, two nodal proteins participating in key pathways inﬂu-
encing vascular disease were prothrombin and apolipoprotein
B-100, affecting blood coagulation and cholesterol transport from
the liver to the tissue respectively. Levels of prothrombin and
apolipoprotein B-100 were found to decrease [Prothrombin: Males
DHA þ EPA Mean iTRAQ log2ratio (SD) ¼ 0.13 (0.20) p ¼ 0.05,
Females DHA þ EPA Mean iTRAQ log2ratio (SD) ¼ 0.48 (0.35)
p ¼ 0.03; Apo B-100: Males DHA þ EPA Mean iTRAQ log2ratio
(SD) ¼ 0.24 (0.16) p ¼ 0.01, Females DHA þ EPA Mean iTRAQ
log2ratio (SD) ¼ 0.15 (0.05) p ¼ 0.02] as a result of the omega-3
supplementation compared to placebo. Ingenuity Pathway Anal-
ysis showed that “molecular transport, lipid metabolism and small
molecule biochemistry” was a signiﬁcantly enriched network in the
plasma proteins affected by the omega-3 intervention in males and
females (score¼ 30, focusmolecules¼ 18 inmales; score¼ 42, focus
molecules ¼ 23 in females) (Fig. 1D).Discussion
This systems biology plasma proteomics study in patients with
NAFLD provides novel insight into the effects of marine omega-3
fatty acid supplementation on plasma proteins related to CVD
and other non-communicable diseases. The study results show that
proteins involved in blood coagulation, inﬂammatory/immune
responses and lipid metabolism were signiﬁcantly altered in the
male and female groups following omega-3 supplementation.Fig. 1. A. Principal Component Analysis using the reporter ion log2ratios of all analysed pro
proﬁle compared to placebo in both male and female cohorts. B. Process Network Analysis
response were signiﬁcantly enriched processes in the plasma proteins that were altered as a
at the end of study vs. baseline as a result of the omega-3 intervention. D. Ingenuity P
signiﬁcantly enriched in the plasma proteins altered as a result of the omega-3 interventioInterestingly, levels of prothrombin and apolipoprotein B-100 were
found to decrease as a result of the omega-3 intervention (Fig. 1C).
Studies have shown that marine omega-3 fatty acids reduce
hypercoagulability, a major risk factor for vascular disease, without
increasing the risk of bleeding [5]. Our results show that the blood
coagulation pathway was signiﬁcantly enriched in the plasma
proteins altered as a result of the omega-3 fatty acid supplemen-
tation (Fig. 1B). Prothrombin, a nodal protein in the blood coagu-
lation pathway, has been reported as a surrogate marker of
cardiovascular risk [6] whereas reduction in plasma prothrombin
levels has been associated with decreased risk of arterial and
venous thrombosis [7].
In vitro experiments and animal studies support an anti-
inﬂammatory and immunomodulatory role for omega-3 fatty
acids [8]. However, evidence from human randomized control trials
is more equivocal. Our study results show that proteins involved in
immune and inﬂammatory responses are affected by omega-3
supplementation (Fig. 1B).
Our results show that DHA þ EPA treatment decreases con-
centrations of apo-B100. Marine omega-3 fatty acid supplementa-
tion is effective in decreasing very-low density lipoprotein (VLDL)
concentrations [9]. Apo B-100 is a major apolipoprotein of the VLDL
particles and apoB-100 concentration is a stronger cardiovascular
disease risk factor, compared to total cholesterol, LDL-c and VLDL-c
levels [10].
The strengths of this study include its RCT design, its long
duration and robust sample size and the application of a global,
untargeted plasma proteomics methodology. One potential limi-
tation is the sample pooling strategy used, which did not permit
the assessment of the anticipated inter-individual heterogeneity in
protein expression levels. Although our approach may haveteins showed that DHA þ EPA treatment had a distinct effect on the plasma proteomic
using MetaCore showed that blood coagulation, immune response and inﬂammatory
result of the omega-3 intervention. C. Plasma proteins that were analysed to be altered
athway Analysis showed that “Lipid Metabolism, Small Molecule Biochemistry” was
n in both sexes.
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treatment effects between individuals, a strength of our approach
is that we are able to provide summary effects of DHA þ EPA
treatment for patients with NAFLD and consequently, any differ-
ences found are likely to be large and therefore potentially more
clinically relevant.Conclusions
Plasma proteomics applied in a randomised, placebo-controlled
trial, lasting between 15 and 18 months, showed that high dose
DHA þ EPA treatment in patients with NAFLD affects multiple
pathways involved in chronic non-communicable diseases.Conﬂicts of interest
The authors have no conﬂict of interest to disclose.Acknowledgments
We thank Roger Allsopp and Derek Coates for establishing the
mass spectrometry facility at the University of Southampton. SDG is
partly supported by the Visiting Professor Program of King Saud
University. ES, PCC and CDB are partly supported by the NIHR
Southampton Biomedical Research Centre. The WELCOME study
was funded by the NIHR Biomedical Research Unit in Nutrition and
Lifestyle. JT was supported by the China Scholarship Council and
the China Postdoctoral Science Foundation (2013T60260).Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.clnu.2018.07.037.
References
[1] Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC, Byrne CD. Improvement
in non-alcoholic fatty liver disease severity is associated with a reduction in
carotid intima-media thickness progression. Atherosclerosis 2015;246:13e20.
[2] Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of
puriﬁed eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver
disease: results from the Welcome* study. Hepatology 2014;60:1211e21.
[3] Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design
and rationale of the WELCOME trial: a randomised, placebo controlled study
to test the efﬁcacy of puriﬁed long chainomega-3 fatty acid treatment in non-
alcoholic fatty liver disease [corrected]. Contemp Clin Trials 2014;37:301e11.
[4] Al-Daghri NM, Alokail MS, Manousopoulou A, Heinson A, Al-Attas O, Al-
Saleh Y, et al. Sex-speciﬁc vitamin D effects on blood coagulation among
overweight adults. Eur J Clin Invest 2016;46:1031e40.
[5] Wachira JK, Larson MK, Harris WS. n-3 Fatty acids affect haemostasis but
do not increase the risk of bleeding: clinical observations and mechanistic
insights. Br J Nutr 2014;111:1652e62.
[6] Paramo JA. Prothrombin fragments in cardiovascular disease. Adv Clin Chem
2010;51:1e23.
[7] Aleman MM, Walton BL, Byrnes JR, Wang JG, Heisler MJ, Machlus KR, et al.
Elevated prothrombin promotes venous, but not arterial, thrombosis in mice.
Arterioscler Thromb Vasc Biol 2013;33:1829e36.
[8] Calder PC. Marine omega-3 fatty acids and inﬂammatory processes: effects,
mechanisms and clinical relevance. Biochim Biophys Acta 2015;1851:469e84.
[9] Padro T, Vilahur G, Sanchez-Hernandez J, Hernandez M, Antonijoan RM,
Perez A, et al. Lipidomic changes of LDL in overweight and moderately hy-
percholesterolemic subjects taking phytosterol- and omega-3-supplemented
milk. J Lipid Res 2015;56:1043e56.
[10] Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al.
Lipoprotein management in patients with cardiometabolic risk: consensus
conference report from the American diabetes association and the American
college of cardiology foundation. J Am Coll Cardiol 2008;51:1512e24.
